Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Bispecific Anti-CD19, Anti-CD20 CAR T Cells for B Cell Malignancies

NCT07166549 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.

NCT NCT07166549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07166549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Bispecific Anti-CD19, Anti-CD20 CAR T Cells for B Cell Malignancies
Lead sponsor
University Hospital, Basel, Switzerland
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
November 30, 2028
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b cell lymphoma, b cell malignancies, b-cell leukemia, bispecific chimeric antigen receptor (car) t cells, relapsed or refractory (r/r) b-cell malignancies